KMT2D, previously also known as MLL2 in humans, is a histone 3 lysine 4 (H3K4) methyltransferase. It has attracted attention as it is within the top 10 most mutated genes in cancer genomes, as well as the main reason behind the congenital disorder Kabuki syndrome. Importantly, in contrast to other cancer genes, the functions of KMT2D have not been clearly established yet. It is believed that KMT2D works through methylating H3K4 in chromatin, a mark of active transcription, and facilitating enhancer mediated transcriptional activation.
We were the first to show that defective KMT2D can contribute to carcinogenesis through DNA damage at the gene loci1. More specifically, we showed that KMT2D interacts with RNA polymerase II at genes and facilitates transcriptional elongation. Inactivation of KMT2D results in DNA damage, transcriptional stress and genomic instability1.
We now plan to investigate the cellular functions of KMT2D in more detail and identify novel ones that are potentially independent of its methyltransferase activity. To this end, we will use immortalised mouse embryonic fibroblasts (MEF) that are inducible KMT2D knock-outs (KO), as well as human colon cancer HCT116 cells that are stable KMT2D KO or only lack the methyltransferase domain of the protein ( ΔSET)1.
We will employ a broad range of standard and cutting edge cellular, molecular, biochemical and bioinformatic techniques to examine, for example, how ionising radiation, chemotherapeutic DNA damage agents and metabolic inhibitors affect cellular functions in mouse and human cells lacking KMT2D or its SET domain. These include, among others, RNA-Seq and qPCRs, protein and chromatin assays, immunofluorescence microscopy, DNA damage and repair, and genomic instability assays1.
The Kantidakis lab is a research-active lab, suitable for enthusiastic and highly motivated PhD candidates. The successful candidate will benefit from working alongside the principal investigator, who will provide direct mentorship and training.
References
1. Kantidakis, T., Saponaro, M., Mitter, R., Horswell, S., Kranz, A., Boeing, S., Aygün, O., Kelly, G.P., Matthews, N., Stewart, A., et al. (2016). Mutation of cancer driver MLL2 results in transcription stress and genome instability. Genes Dev 30, 408–420. 10.1101/gad.275453.115.